echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Ganli Pharmaceutical's research product GLR2007 was recognized as an orphan drug by the European Commission

    Ganli Pharmaceutical's research product GLR2007 was recognized as an orphan drug by the European Commission

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 6, Ganli Pharmaceutical issued an announcement stating that it had recently received an official written reply from the European Commission ("EC"), granting the company's innovative drug cyclin-dependent kinase 4/6 (CDK4/6) inhibition (Hereinafter referred to as "GLR2007") orphan drug qualification certification for the treatment of glioma.


    GLR2007 is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.


    This time, Ganli Pharmaceutical's innovative drug GLR2007 was successfully approved by the European Commission (EC) as an orphan drug for the treatment of glioma.


    As of September 30, 2020, the GLR2007 project has invested a total of 57.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.